The impact of depression and anxiety treatment on biological aging and metabolic stress: study protocol of the MOod treatment with antidepressants or running (MOTAR) study

Bianca A. Lever-van Milligen 1,2*, Josine E. Verhoeven 1,2, Lianne Schmaal 1,2, Laura S. van Velzen 1,2, Dóra Révész 1,2, Catherine N. Black 1,2, Laura K. M. Han 1,2, Melany Horsfall 1,2, Neeltje M. Batelaan 1,2, Anton J. L. M. van Balkom 1,2, Digna J. F. van Schaik 1,2, Patricia van Oppen 1,2 and Brenda W. J. H. Penninx 1,2

Abstract

Background: Depressive and anxiety disorders have shown to be associated to premature or advanced biological aging and consequently to adversely impact somatic health. Treatments with antidepressant medication or running therapy are both found to be effective for many but not all patients with mood and anxiety disorders. These interventions may, however, work through different pathophysiological mechanisms and could differ in their impact on biological aging and somatic health. This study protocol describes the design of an unique intervention study that examines whether both treatments are similarly effective in reducing or reversing biological aging (primary outcome), psychiatric status, metabolic stress and neurobiological indicators (secondary outcomes).

Methods: The MOOD Treatment with Antidepressants or Running (MOTAR) study will recruit a total of 160 patients with a current major depressive and/or anxiety disorder in a mental health care setting. Patients will receive a 16-week treatment with either antidepressant medication or running therapy (3 times/week). Patients will undergo the treatment of their preference and a subsample will be randomized (1:1) to overcome preference bias. An additional no-disease-no-treatment group of 60 healthy controls without lifetime psychopathology, will be included as comparison group for primary and secondary outcomes at baseline. Assessments are done at week 0 for patients and controls, and at week 16 and week 52 for patients only, including written questionnaires, a psychiatric and medical examination, blood, urine and saliva collection and a cycle ergometer test, to gather information about biological aging (telomere length and telomerase activity), mental health (depression and anxiety disorder characteristics), general fitness, metabolic stress-related biomarkers (inflammation, metabolic syndrome, cortisol) and genetic determinants. In addition, neurobiological alterations in brain processes will be assessed using structural and functional Magnetic Resonance Imaging (MRI) in a subsample of at least 25 patients per treatment arm and in all controls.

(Continued on next page)
Background
Depressive and anxiety disorders are common comorbid conditions with a large impact on public health [1, 2]. Meta-analyses show that persons with depressive and anxiety disorders have increased risks for the onset of cardiovascular diseases, diabetes, stroke, obesity [3], and advanced physical [3, 4] and cognitive decline [5]. In other words, depressive and anxiety disorders need to be considered as an important risk factor for a multitude of aging-related conditions. Dysregulation of physiological stress systems such as inflammation, hyperactivity of the HPA-axis and metabolic dysregulation [6, 7] have been suggested to partly underlie these associations. Additionally, persons with depressive and anxiety disorders are found to be subject to advanced biological aging. Furthermore, these physiological stress systems may also play a role in recovery mechanisms of depression and anxiety disorders.

Two treatment regimens for depressive and anxiety disorders that have shown to be effective are antidepressants and running therapy [8–11]. It is, however, unclear whether they could beneficially affect biological aging and physiological stress-systems dysregulations. Well-designed studies looking into the underlying physiological pathways of both treatments are lacking. It has been suggested that these interventions may work through different pathophysiological mechanisms. Despite their comparable effectiveness on mental health outcomes [8], running therapy may have a more beneficial impact on somatic health indicators including biological aging [12]. This intervention study examines and compares the impact of antidepressant medication and running therapy on biological aging, metabolic stress and neurobiological abnormalities related to depression and anxiety.

Depressive and anxiety disorders and biological aging
In line with their negative impact on a multitude of aging-related somatic conditions, depression and anxiety disorders have found to be related to more advanced biological aging. This is for instance evidenced by shorter telomeres found in depression and/or anxious patients as compared to healthy controls [13–16]. Telomere length (TL), a relatively well-studied marker of cellular age, integrates the cumulative lifetime burden of genetic and environmental factors dependent on chronological age [17], and predicts several aging-related diseases and early mortality [18]. Telomeres are tandem repeated DNA sequences that form protective caps at chromosome ends [19] which can be elongated by telomerase enzymes. High telomerase activity has protective functions for aging and cell death and lower telomerase activity is linked to aging-related disease factors [20–22]. Some studies suggest that telomerase activity is elevated in the presence of a depression diagnosis [23], possibly as an attempt to compensate for the loss of TL. However, another study found decreased telomerase activity in a chronically stressed sample [24], leaving it unclear whether increased activity of the enzyme is a sign of improved health or rather a compensatory mechanism. The extent to which depression and anxiety treatment impacts the telomere/telomerase system has not been extensively examined [25].

Depressive and anxiety disorders, metabolic stress and neurobiological abnormalities
In various studies and meta-analyses, depressive and anxiety disorders have been linked to physiological alterations of central bodily stress systems: systemic inflammation [7, 26, 27] and oxidative stress [6], hyperactivity of the hypothalamus-pituitary adrenal (HPA) axis [28], a dysregulated autonomic tone [29, 30] accompanied with metabolic syndrome dysregulations [31]. Metabolic and physiological stress system dysregulations could contribute to the process of advanced biological aging as they have shown to affect TL and the telomere maintenance system [32–34].

Physiological stress systems also impact the structural and functional integrity of the brain, such as hippocampal volume, prefrontal cortex (PFC) morphology, and activity of the amygdala, insula and anterior cingulate cortex (ACC) [35–38], albeit inconsistently [39]. These are key brain regions implicated in depression and anxiety as there is converging evidence for widespread but subtle structural alterations in prefrontal regions such as the ACC, dorsomedial and orbitofrontal cortex, posterior cingulate cortex, insula, and the hippocampus [40–45]. There is also some evidence for rostral ACC, amygdala and medial PFC hyperactivation during emotional processing, while dorsal regions may be hypoactive in people with depression or anxiety disorders [46–49], although findings have been inconsistent across studies [50].
Depressive and anxiety disorder treatment and physiological changes

Commonly prescribed selective serotonin re-uptake inhibitors (SSRI) have shown to be effective in depression and anxiety treatment [9, 51]. Some -although limited- evidence exists suggesting that SSRI treatment results in decreased cortisol [52], inflammatory [53] and antioxidant [54] levels. A recent review suggested a role for telomerase activity mediating the beneficial effects of antidepressants medication [55], possibly by promoting cell survival and/or function both in the brain and in the periphery. Only a few studies examined the association between antidepressant treatment and the telomere system and found shorter leukocyte telomere length (LTL) in patients who did not respond to antidepressants compared to those who did respond [56, 57]. Sample sizes of above-mentioned studies were relatively small, thus associations between antidepressant response and telomere length/telomerase activity remain to be extensively explored.

A similarly effective intervention is running therapy [10, 58, 59]. Running therapy works through the direct impact of aerobic exercise on opioid [60, 61], monoaminergic mechanisms [62] and regional cerebral blood flow [63]. The impact of running therapy has also been shown to reduce oxidative stress [64], inflammation [65–67], and cortisol [68]. Exercise has also shown to have beneficial impact on TL in a cancer population with higher telomerase activity emerging after 3 months of exercise, which was paralleled by decreases in psychological distress [69], a finding confirmed in other research [12, 70–72]. Two studies comparing running therapy and SSRI treatment confirmed a similar effectiveness for depression [8, 73] and anxiety disorders [74]. Nevertheless, these interventions probably work through different pathophysiological mechanisms and may have different impact on biological aging.

Objective

This intervention study examines and compares the impact of antidepressant medication and running therapy on biological aging (primary outcome) and psychiatric status, metabolic stress and neurobiological abnormalities relevant for depression and anxiety disorders (secondary outcomes). This study also examines to what extent treatment-induced improvement in psychiatric status parallels with improvement of biological aging, metabolic stress and neurobiological abnormalities. Furthermore, this study compares the pre- and posttreatment outcomes to the physiological stress parameters of the no-disease-no-treatment control group.

Methods

Study design

The MOod Treatment with Antidepressant or Running (MOTAR) study is a 16-week intervention study with two treatment arms: 1) antidepressant medication and 2) running therapy (see Fig. 1). In total, 160 patients with a depressive and/or anxiety disorder receive antidepressants or running therapy. Depressive and anxiety disorders are highly comorbid [75], also over time [76, 77], their underlying pathophysiology is largely comparable and both disorders are treated with similar treatments [10, 51, 74, 78]. A randomised controlled trial is the preferred method to compare two interventions, but also comes with limitations: quite some patients do not agree with random treatment assignment, and therefore, studies may result in selective inclusion of subjects which hampers the generalizability of results. Consequently, we decided to conduct a pragmatic study (resembling a partially randomised preference patients design (PRPP) [79]. First, patients without strong preference for treatment allocation are randomly allocated (1:1) to either antidepressant medication or running therapy. The SPSS random generator (SPSS, version 20.0) is used to randomise these participants. Subsequently, persons who were not willing to be randomised but are willing to participate in the study, were allocated to their preferred intervention. In order to be certain that no age differences arise, randomization is stratified by age in two groups (cut
off 40 years). Further, in a subset of at least 50 subjects (25 from both treatment conditions) neuroimaging (Magnetic Resonance Imaging (MRI) data will be collected. A no-disease-no-treatment-control group (N = 60) will be examined to compare health, physiological and neurobiological indicators between persons with and without depression and anxiety disorders at baseline, and allows checks on whether improvements over time after treatment completely restores health and physiological levels to those of healthy controls.

Recruitment and study settings
Between 2012 and 2019, patients are recruited when (newly) enrolled at GGZ inGeest (mental health organization in the surroundings of Amsterdam, The Netherlands) with depressive and/or anxiety disorders. Patients receive information about the study during the intake and are asked for their participation. During a telephone screening, in- and exclusion criteria are checked and when consent is given, patients undergo a baseline assessment before starting their treatment. All patients are also asked to participate in the MRI study substudy.

The no-disease-no-treatment-control group is recruited through advertisements in the area and through the website www.motar.nl. Persons receive information about the study and are asked for their participation. Patients and controls are matched on the basis of age, sex and educational level. In- and exclusion criteria are checked and after given consent, the healthy persons only undergo a baseline and neuroimaging assessment.

Eligibility criteria
Inclusion criteria of the patient sample include: having a current depressive disorder (major depressive disorder) or anxiety disorder (social phobia, generalized anxiety disorder, panic disorder with or without agoraphobia) as ascertained by the Diagnostic and Statistical Manual of Mental Disorders – Fourth edition (DSM-IV) algorithms with the CIDI (Composite International Diagnostic Interview) [80] and being aged between 18 and 70 years. Exclusion criteria are: 1) use of antidepressants in last 2 weeks, 2) current use of other psychotropic medication, except for the use of benzodiazepines with stable usage, 3) regular exercising more than once a week, 4) primary severe, clinically diagnosed psychiatric diagnosis other than a depressive or anxiety disorder, 5) evidence of acute suicidal risk (based on clinical view), 6) medical contra-indications to running therapy or antidepressants (e.g. serious heart problems) as confirmed by a physician.

Additional exclusion criteria for the MRI sub-study are major internal or neurological disorders, pregnancy and known contra-indications for MRI investigations, such as the presence of metal objects (e.g. pacemaker, arteriovenous clips) or claustrophobia.

Consent procedure, baseline and follow-up assessments
Informed consent approved by the Medical Ethical Committee VU University Medical Centre has to be signed before starting the baseline assessment. During a 4-h face-to-face baseline assessment a wide range of data will be collected, including demographic information, a diagnostic psychiatric interview, a medical examination, a cycle ergometer test, collection of saliva, urine, and blood and various self-reported clinical questionnaires. At week 6 and week 10 depression and anxiety symptom severity will be assessed by self-report questionnaires. At week 16 and week 52, the assessments will be repeated in the patient sample (see Fig. 1). For each face to face assessment, the patient will receive a gift voucher of €50. MRI measurements consist of a clinical interview and a neuroimaging session with a total duration of approximately 2.5 h. For each MRI measurement, the patient will receive a gift voucher of €25.-. The control group will undergo a baseline and neuroimaging assessment, but no follow-up assessments. The control participants will receive a gift voucher of €50. Table 1 gives an overview of the data collection.

Intervention
Participants will undergo a intervention of 16 weeks since this period has shown to be sufficient to decrease depressive and anxiety symptoms and to impact on physiological stress after antidepressant therapy [101] or running therapy [102, 103].

Antidepressant medication
Patients will receive standardized treatment with escitalopram, a selective serotonin reuptake inhibitor (SSRI) which has documented efficacy, a rather favorable side effect profile, is recommended as first-step treatment in both the General Practitioner (NHG Standardized depressive disorder and anxiety disorder (in Dutch)) and Psychiatry treatment guidelines (Multidisciplinary guidelines depression and anxiety (in Dutch)), and is one of the most commonly prescribed antidepressants [101, 104]. An initial dosage of 10 mg per day of escitalopram is used. Medication management is provided by a psychiatrist who meets each patient at study onset and at weeks 2, 6, 10 and 16. At these meetings, the psychiatrist evaluates treatment response and side effects, and titrates dosage (to a maximum of 20 mg) according to the multidisciplinary depression/anxiety guidelines until a clinically effective
| Primary outcomes | Instrument | Method  | Week 0 | Week 6 | Week 10 | Week 16 | Week 52 |
|------------------|------------|---------|--------|--------|---------|---------|---------|
| Biological aging: telomere length, telomerase activity | Fasting blood samples | Blood | X | – | – | X | X |
| Secondary outcomes | | | |
| Biological and general health indicators | | |
| Biomarkers (inflammation, metabolic syndrome) | Fasting blood samples | Blood | X | – | – | X | X |
| Gene-expression (RNA) | Fasting blood samples | Blood | X | – | – | X | X |
| HPA-axis (cortisol) | 2 days of 6 saliva samples | Saliva | X | – | – | X | X |
| Oxidative stress | Urine sample | Urine | X | – | – | X | X |
| Autonomic nervous system | Electro + impedance cardiography, heart rate variability [81] | ME | X | – | – | X | X |
| Blood pressure | Systolic and diastolic BP | ME | X | – | – | X | X |
| Body composition | Weight, height, waist+ hip circumference | ME | X | – | – | X | X |
| Physical condition | Astrand sub max test [82] | ME | X | – | – | X | X |
| Muscle strength | Hand grip strength [81] | ME | X | – | – | X | X |
| Lung function | Peak expiratory flow [82] | ME | X | – | – | X | X |
| Pain | Chronic graded pain scale [83] | Int | X | – | – | X | X |
| Somatization | Short somatization questionnaire [84] | SR | X | – | – | X | X |
| Disability severity | WHO-DAS II [85] | SR | X | – | – | X | X |
| Depressive and anxiety disorders | | |
| Presence of MDD | CIDI: MDD [78] | Int | X | – | – | X | X |
| Presence of anxiety dis | CIDI: SocPhob, Agora, GAD, PA [78] | Int | X | – | – | X | X |
| Course of symptoms | Life-chart [86] | Int | X | – | – | X | X |
| Severity of depression | Inventory of depressive symptoms [87] | SR | X | X | X | X | X |
| Severity of anxiety | Beck anxiety index [88] and Fear questionnaire [89] | SR | X | X | X | X | X |
| Sleep | Insomnia Rating Scale [90] | Int | X | – | – | X | X |
| Descriptive variables, potential confounding covariates and potential mediating variables | | |
| Age, gender, ethnicity | Standard questions | Int | X | – | – | – | – |
| Socio-economic status | Education, income, occupation | Int | X | – | – | – | – |
| Physical activity | SQUASH questionnaire [91] | SR | X | – | – | X | X |
| Smoking | Past + current smoking questions | SR | X | – | – | – | X |
| Medication use | Drug container observation | Int | X | – | – | X | X |
| Regular alcohol intake | AUDIT questionnaire [92] | SR | X | – | – | – | X |
| Somatic diseases | Presence + symptoms of disease | Int | X | – | – | X | X |
| Health care | Perceived need of care [93] | Int | X | – | – | X | X |
| Work and disability | Tic-P questionnaire [94] | Int | X | – | – | X | X |
| Personality | NEO-FFI questionnaire [95] | SR | X | – | – | X | X |
| Locus of control | Pearlin & Schooler mastery scale [96] | SR | X | – | – | X | X |
| Depression vulnerability | LEIDS-R questionnaire [97] | SR | X | – | – | X | X |
| Anxiety vulnerability | Anxiety sensitivity index [98] | SR | X | – | – | X | X |
| Experimental cognitive task | Implicit association test (IAT) [99] | CT | X | – | – | X | X |
| Experimental memory task | Digit Span (WAIS) [100] | Int | X | – | – | X | X |
| Important neg + pos life events | Brugha questionnaire [101] | Int | X | – | – | X | X |
dosage is achieved. Following the medication protocol, if the initial SSRI is poorly tolerated, the psychiatrist can switch prescription to another SSRI drug (sertraline, dosage of 50 mg to a maximum of 150 mg). Adherence to treatment is evaluated by a patient’s diary and administration log by the psychiatrist. After 16 weeks of treatment, a research assessment will take place and further treatment is conducted following clinical guidelines.

**Running therapy**

Therapy consists of three 45-min outdoor running sessions per week, in line with the public health recommendations by CDC/American College of Sports Medicine [105] and its earlier successful effects on depression and anxiety [74, 106]. Patients will be gradually assigned individual training ranges equivalent to 70–85% of their heart rate reserve, calculated from the heart rate achieved during a cycle ergometer test with the formula of Karvonen [107]. This intensity level was confirmed to be effective in decreasing depressive symptoms [103]. During the screening phase and during baseline assessment, so before formal inclusion to the study, potential physical and/or somatic problems and use of medication are administrated. When serious somatic conditions are signalled, the person’s own physician will be contacted and consulted in order to discuss potential study participation. Furthermore, at the beginning of the running intervention, the running therapist discusses experience of exercise in the past, and will provide information about food, moisture balance, fatigue, injuries, sleep and recovery. The running therapy intervention was conducted at a medical institution (GGZinGeest) where there is always a physician approachable. Running sessions will be organized and supervised by qualified staff, starting with a 10-min warming-up exercise period followed by 30 min of jogging at an intensity that maintains heart rate within the assigned training range (starting in the first 4 weeks at 50–70% of heart rate reserve and in the subsequent 12 weeks at 70–85% of heart rate reserve), finishing with 5 min of cooling-down exercises. During the running sessions, all subjects wear a heart rate monitor. Heart rate will be confirmed three times per session to ensure that patients are exercising within the prescribed exercise training ranges. Data of the heart rate monitor will be uploaded after sessions and used to encourage study compliance. Patients are stimulated to participate in all three organized group sessions, but if strongly preferred, home-based individual running is allowed once per week. The trainer monitors training attendance. The size of the running group is on average 5 or 6 patients. Both interventions were conducted using evidence-based clinical guidelines (https://www.nhg.org/sites/default/files/content/nhg_org/uploads/multidisciplinaire_richtlijn_depressie_3e_revisie_2013.pdf). Adverse events in both treatment programs will be signalled and reported the medical ethical committee. After 16 weeks of treatment, a research assessment will take place and further treatment is conducted following clinical insights by the responsible clinician.

**Outcomes**

**Primary outcomes**

The primary outcome of this trial is the change in biological aging, measured through TL and telomerase activity before the start and at the end of the intervention. TL has been shown to be correlated to functioning of multiple physiological stress systems such as the immune-inflammatory system, the hypothalamus-pituitary-adrenal (HPA)-axis and the autonomic nervous system (ANS) [33, 34] and therefore picks up potential improvement in various underlying mechanisms. In addition, TL has been shown to be predictive of various somatic health outcomes.

---

**Table 1** Collected information on central (mental) health outcomes in MOTAR (Continued)

| Instrument | Instrument Method | Week 0 | Week 6 | Week 10 | Week 16 | Week 52 |
|------------|-------------------|--------|--------|---------|---------|---------|
| Childhood Trauma | Youth Trauma questionnaire [102] | SR | X | – | – | – |
| Family history | Family history inventory | Int | X | – | – | – |
| Neuroimaging assessment (subsample) | Health behavioral measures | MRI | x | – | – | x | x |
| Verbal episodic memory | 15-words test [103] | MRI | x | – | – | x | x |
| Task-related brain activity | Emotional face matching paradigm and N-back paradigm [104] | MRI | x | – | – | x | x |
| Brain network connectivity | Resting state MRI images | MRI | x | – | – | x | x |

SR self-report, Int interview, Blood data collection via fasting blood sample, CT computer task, ME medical examination
including mortality. TL has earlier been used in studies examining the effects of lifestyle interventions [72, 108, 109] and has shown sensitive to change, even at rather short term, interventions were linked to less shortening of TL. In addition to explore the underlying telomere system dynamics, we also will measure telomerase activity, as was done in Wolkowit et al. (2012) [23]. TL will be measured from purified DNA samples from peripheral blood mononuclear cells that were stored frozen at −80 °C using a quantitative polymerase chain reaction (qPCR)-based assay. Telomerase enzymatic activity will be measured by the Telomerase Repeat Amplification Protocol (TRAP149) using the commercial TRAPeze kit (Chemicon, Upstate/CHEMI-CON, Temecula, CA, USA) [23]. Less shortening of TL after treatment will be seen as reverse of biological aging.

Secondary outcomes

Biological and general health indicators Biomarkers of physiological health will be gathered through fasting blood samples, 24-h urine, and six saliva samples were taken at 1 day covering morning awakening response (at awakening and at 30, 45 and 60 min later), afternoon (at 6 pm) and evening levels (at 10 pm) to e.g. examine inflammatory markers, cortisol levels, metabolic syndrome abnormalities, DNA and oxidative stress. Activity of the autonomic nervous system will be measured using the ambulatory monitoring system (VU-ams) of which reliability and recording methodology have been described previously [110]. Furthermore, blood pressure, fitness (using bicycle ergometer with the Astrand method [111]), hand grip strength (by Jamar hand grip meter) [112] and lung function (using Mini Wright peak flow meter) [113] will be tested. The chronic graded pain scale [114] will be taken to evaluate pain, somatization will be assessed with the short somatization scale [115] and disability severity will be gathered using the WHODAS II [116].

Depressive and anxiety disorders The presence of depressive disorders (Major Depressive Disorder) and anxiety disorders (social phobia, generalized anxiety disorder, panic disorder and agoraphobia) will be established using the CIDI. The CIDI is a valid and reliable instrument to assess depressive and anxiety disorders [80] and will be administered by specially trained research staff. The type and number of depressive and anxiety disorders will be compared across the intervention groups and, if necessary, these clinical characteristics will be considered as covariates in the main analyses. Fluctuation of depression and anxiety during follow-up will be examined using the Lifechart method [81]. Severity of depression is measured using the 30-item Inventory of Depressive Symptomatology (IDS-SR30) [82]. Severity of anxiety is measured with the 21-item Beck Anxiety Inventory (BAI) [83]. For both scales higher scores mean higher symptom severity. Phobia symptoms will be measured with the Fear Questionnaire [84]. Sleep duration and quality will be examined with the Insomnia Rating Scale [85]. Psychotropic medication use was assessed during the interview at baseline, 16 and 52 weeks by inspection of the participant’s medication containers. It contained lifetime history of use as well as use during the study and was classified using the World Health Organization Anatomic Therapeutic Chemical (ATC) classification (World Health Organization Centre for Drug Statistics Methodology, 2010).

Neuroimaging assessment In a subsample of the patients and in the healthy controls a neuroimaging assessment will be taken using the 3 T Philips Intera MR system. The 15-words test, a Dutch version of the Rey auditory verbal learning test [98] will be performed outside the scanner to assess verbal episodic memory. Anatomical T1-weighted and diffusion tensor imaging (DTI) scans will be obtained to assess grey and white matter structure. An emotional face matching paradigm [99] and N-back paradigm [100] will be employed to examine task-related brain activity. Finally, brain network connectivity will be examined during rest by acquiring resting state fMRI images.
Sample size
Published running therapy and antidepressant intervention studies in non-psychiatric groups have yielded effect sizes for changes in biological aging ranging from 0.5 [74] to 1.2 [112]. When using the minimum effect size found (0.5), 80% power and \( p = 0.05 \), we need 63 subjects per group. Considering a dropout of 20%, \( n = 76 \) patients per group are needed to illustrate significant antidepressant and running therapy effects on biological aging in a patient group. That is why we strive for 80 patients per group, and 160 total.

As described by Thirion, functional MRI analyses require a minimum of 25 subjects per group for adequate statistical power [117]. In addition, we aimed to include 60 healthy controls to allow additional comparisons in outcomes between controls and patients.

Organisation, and quality insurance and data management
Compliance with antidepressant medication or running therapy is assessed using patient’s and therapeutic logs. Patients who withdraw from the intervention will be asked reason(s) for drop out and they will be motivated to continue the measurements with the purpose to minimize loss of follow-up data and to make the intention to treat analysis and per-protocol analysis possible.

Research data will be collected by a coded participant number. Interviews will be conducted by computer and questionnaires by paper and will be entered into the system by the research assistant. An administrative database will be used to ensure timely assessments. The data manager will make back-ups for the monitoring of overall progress and data quality.

Statistical analysis plan
Missing data will be inspected and handled via full information maximum likelihood. Mixed model regression analyses will be conducted to estimate the effect size of both.

Interventions on biological aging and psychiatric status, metabolic stress and neurobiological abnormalities. Per protocol analyses within intervention groups will be conducted to evaluate whether change of biological aging and metabolic stress is a function of protocol adherence. The two intervention groups will be compared using mixed models or generalized estimating equations (GEE) to assess the longitudinal change of biological aging, physiological and metabolic stress and psychiatric symptoms. These models will also compare physiological and clinical effects of those who are willing and not willing to be randomised to check the impact of a patients’ preferred or allocated intervention. Furthermore, pre- and posttreatment outcomes to physiological stress parameters will be compared to the no-disease-no-treatment control group using regression analyses.

Trial status
The MOTAR study was approved by the Medical Ethics Committee of the VU University Medical Center Amsterdam and registered with the Netherlands Trial Register under NTR3460. Recruitment commenced in September 2012 and is ongoing.

Discussion
A wide range of treatment programs for depressive and anxiety disorders are available but it remains largely unknown whether the impact of these programs on biological aging, metabolic stress and neurobiological abnormalities are comparable. Treatment with antidepressant medication or running therapy have both shown to be effective in depression and anxiety, but a well-designed comparative study of these treatment strategies and their impact on physiological and neurobiological processes is currently lacking. As the number and type of clinician contacts between groups are not similar, this could be underlying clinical improvement. However, the interventions in this trial were developed in line with current guideline standards and therefore are as much as possible reflective of regular clinical care treatments.

This intervention study is designed to examine and compare the impact of antidepressant medication and running therapy on changes of both mental and physiological health, including biological aging, metabolic stress and neurobiological function and whether these pre- and posttreatment outcomes are comparable with persons without a psychiatric status. It is expected that this study provides more detailed information about underlying biological mechanisms of depression and anxiety treatment effects. Having insight in the favourable physiological stress effects of these treatment regimens could probably also be helpful in increasing the effectiveness of personalised medicine.

Abbreviations
ACC: Anterior cingulate cortex; Agora: Agoraphobia; ASI: Anxiety sensitivity index; BAI: Beck’s anxiety index; BP: Blood pressure; CDC: Center for disease control; CIDI: Composite international diagnostic interview; CT: Computer task; DSM-IV: Diagnostic and statistical manual of mental disorders fourth edition; DTI: Diffusion tensor imaging; GAD: Generalised anxiety disorder; HPA: Hypothalamus-pituitary-adrenal; IAT: Implicit association task; IDS-SR: Inventory of depressive symptomatology; LTL: Leukocyte telomere length; MDD: Major depressive disorder; ME: Medical examination; MOTAR: Mood treatment with antidepressants or running; MRI: Magnetic resonance imaging; NEO-FFI: Neuroticism- extraversion-openness five-factor inventory; NHG: Nederlands huisartsen genootschap; PA: Panic disorder; PFC: Prefrontal cortex; qPCR: Quantitative polymerase chain reaction; SQUASH: Short questionnaire to assess health enhancing physical activity; SRR: Self-report; SSR: Selective serotonin re-uptake inhibitors; TIC-P: Treatment inventory of costs in patients; TL: Telomere length; TRAP: Telomerase repeat amplification protocol; VU-ams: VU university ambulatory monitoring system; WAIS: Wechsler adult intelligence scale; WHODAS: World health organisation disability assessment schedule.
Authors’ contributions
BP designed and got funding for the study. PO, DS, AB, NM, LM contributed to the conception of the study. BL coordinated the recruitment of patients and the data collection. LS, DR, CB, LH, and MH helped conducting the study. BL and JV drafted the first manuscript. PO, DS, AB, NM, LM, LS, DR, CB, LH, and MH commented on the manuscript. All authors read and approved the last version of the manuscript.

Funding
The MOTAR study was funded by NWO VIDI grant number 91811602 of B.W.J.H. Penninx. NWO had no role in the design of the study, the collection, analysis and interpretation of the data, or in the preparation, review, or approval of the manuscript.

Availability of data and materials
MOTAR-data can be requested through the submission of an analysis plan. Instructions can be found on the website www.motar.nl

Ethics approval and consent to participate
Ethical and professional guidelines will be followed at all times, in line with Good Clinical Practice guidelines. Institutional review board approval has been obtained from the Medical Ethics Committee of VU Medical Centre Amsterdam, the Netherlands (May 23, 2012, VUmc METC registration number: 2012–064). All participants gave written informed consent prior to baseline assessment. The MOTAR study was registered in the Trial register of The Netherlands: Trialregister.nl, Number of identification: NTR3460.

Consent for publication
Not applicable.

Competing interests
BP has received (non-related) funding from Jansen Research and Boehringer Ingelheim. All other authors declare that they have no conflicts of interest.

Received: 3 June 2019 Accepted: 11 December 2019
Published online: 30 December 2019

References
1. Murray CL, Lopez AD. Alternative projections of mortality and disability by cause 1990-2020: global burden of disease study. Lancet. 1997;349:1498–504.
2. Ferrari AJ, Charlson FJ, Norman RE, Patten SB, بلدیان G, Murray CJ, et al. Burden of depressive disorders by country, sex, age, and year: findings from the global burden of disease study 2010. PLoS Med. 2013;10:e1001547.
3. Penninx BW, Milaneschi Y, Lamers F, Vogelzangs N. Understanding the global burden of depressive disorders by country, sex, age, and year: findings from the global burden of disease study 2010. PLoS Med. 2013;10:e1001547.
4. Roy-Byrne PP, Davidson KW, Kessler RC, Asmundson GJ, Goodwin RD, et al. Accelerating research on biological aging and mental health. Psychoneuroendocrinology. 2019;106:293–311.
5. Howren MB, Lamkin DM, Suls J. Associations of depression with C-reactive protein, IL-1, and IL-6: a meta-analysis. Psychosom Med. 2009;71:171–86.
6. Hoge EA, Brandtsteder K, Mosher S, Pollack MH, Wong KK, Simon NM. Broad spectrum of cytokine abnormalities in panic disorder and posttraumatic stress disorder. Depress Anxiety. 2009;26:447–55.
7. Stetler C, Miller GE. Depression and hypothalamic-pituitary-adrenal activation: a quantitative summary of four decades of research. Psychosom Med. 2011;73:114–26.
8. Fisher AJ, Newman MG. Heart rate and autonomic response to stress after experimental induction of worry versus relaxation in healthy, high-worry, and generalized anxiety disorder individuals. Biol Psychol. 2013;98:65–74.
9. Kemp AH, Quintana DS, Gray MA, Flemingham KL, Brown K, Jim TP. Impact of depression and antidepressant treatment on heart rate variability: a review and meta-analysis. Biol Psychiatry. 2010;67:1067–74.
10. Ghanie Geshliah R, Paszad N, Sayehmiri K. The relationship between depression and metabolic syndrome: systematic review and meta-analysis study. Iran Red Crescent Med J. 2016;18:168.
11. Canero JJ, Stenvinkel P, Fellstrom B, Querechi AR, Lamb K, Heimburger O, et al. Telomere attrition is associated with inflammation, low fetuin-a levels and high mortality in prevalent hypercholesterolemia patients. J Intern Med. 2008;263:302–12.
12. Revesz D, Verhoeven JE, Milaneschi Y, de Geus EJC, Wolkowitz OM, Penninx BWJH. Dysregulated physiological stress systems and accelerated cellular aging. Neurobiol Aging. 2014;35:1422–30.
13. Revesz D, Verhoeven JE, Milaneschi Y, Penninx BWJH. Depressive and anxiety disorders and short telomere telomere length: mediating effects of metabolic stress and lifestyle factors. Psychol Med. 2016;46(11):2373–49.
14. Muscatell KA, Dedovic K, Slavich GM, Jarcho MR, Bower JE, et al. Greater amygdala activity and dorsomedial prefrontal-amygdala coupling are associated with enhanced inflammatory responses to stress. Brain Behav Immun. 2015;49:346–53.
15. Satzazabal GL, Zhu VC, Mazoyer B, Dufouil C, Tzourio C. Circulating IL-6 and CRP are associated with MRI findings in the elderly: the 3C-DION study. Neurology. 2012;78:20–7.
16. Slavich GM, Way BM, Eisenberger NI, Taylor SE. Neural sensitivity to social rejection is associated with inflammatory responses to social stress. Proc Natl Acad Sci U S A. 2010;107:14817–22.
38. van Velsen LS, Wijdeveld M, Black CN, van Tol MJ, van der Wee NJA, Veltman DJ, et al. Oxidative stress and brain morphological changes in individuals with depression, anxiety and healthy controls. Prog Neuro-Psychopharmacol Biol Psychiatry. 2017;76:140–4.

39. Kremen WS, O'Brien RC, Panizzon MS, Prom-Wormley E, Eaves LJ, Essen SA, et al. Saliary cortisol and prefrontal cortical thickness in middle-aged men: a twin study. NeuroImage. 2010;53:1093–102.

40. Bora E, Harrison BJ, Davey CG, Yucel M, Pantelis C. Meta-analysis of volumetric abnormalities in cortico-striato-pallidal-circuit in major depressive disorder. Psychol Med. 2012;42:671–81.

41. Koobsch PC, van Haren NE, Lentsveld-Mulders GJ, Hulshoff Pol HE, Kahn RS. Brain volume abnormalities in major depressive disorder: a meta-analysis of magnetic resonance imaging studies. Hum Brain Mapp. 2009;30:379–53.

42. Schmaal L, Veltman DJ, Van Erp TG, Samann PG, Frodl T, Jahanshad N, et al. Subcortical brain alterations in major depressive disorder: findings from the ENIGMA major depressive disorder working group. Mol Psychiatry. 2016;21:806–12.

43. Schmaal L, Hiar DI, Samann PG, Hall GB, Baune BT, Jahanshad N, et al. Cortical abnormalities in adults and adolescents with major depression based on brain scans from 20 cohorts worldwide in the ENIGMA major depressive disorder working group. Mol Psychiatry. 2017;22:900–9.

44. van Tol ML, van der Wee NJA, van den Heuve OL, Nielen MMA, Demenescu LR, Aleman A, et al. Regional brain volume in depression and anxiety disorders. Arch Gen Psychiatry. 2010;67(10):1002-11.

45. Videbech P, Ravindike B. Hippocampal volume and depression: a meta-analysis of MRI studies. Am J Psychiatry. 2004;161:957–66.

46. Rive MM, van Roijen JG, Veltman DJ, Philips M, Schene AH, Ruhe HG. Neural correlates of dysfunctional emotion regulation in major depressive disorder. A systematic review of neuroimaging studies. Neurosci Biobehav Rev. 2013;37:259–53.

47. Jaworska N, Yang XR, Knott V, MacQueen G. A review of fMRI studies during exercise training and plasma C-reactive protein and interleukin-6 in elderly people. J Am Geriatr Soc. 2008;56:2045–52.

48. You T, Nicklas BJ. Effects of exercise on adipokines and the metabolic syndrome. Curr Diab Rep. 2008;8:7–11.

49. Karacay K. The effect of exercise on leptin, insulin, cortisol and lipid profiles in obese children. J Int Med Res. 2009;37:472–8.

50. Ornish D, Lin J, Daubenmier J, Weidner G, Epe E, Kemp C, et al. Increased telomerase activity and comprehensive lifestyle changes: a pilot study. Lancet Oncol. 2008;9:1048–57.

51. Du M, Prescott J, Kraft P, Han J, Giovanniucci E, Hankinson SE, et al. Physical activity, sedentary behavior, and leukocyte telomere length in women. Am J Epidemiol. 2012;175:414–22.

52. Oththun IB, Scura A, Berardelli F, Alses N, Bronstad E, Rehn T, et al. Telomere length and long-term endurance exercise: does exercise training affect biological age? A pilot study. PLoS One. 2012;7:e52769.

53. Puterman E, Lin J, Kraus J, Blackburn EH, Epe E. Determinants of telomere attrition over 1 year in healthy older women: stress and health behaviors matter. Mol Psychiatry. 2015;20:29–35.

54. Blumenthal JA, Babyak MA, Moore KA, Craighhead WE, Herman S, Khatir P, et al. Effects of exercise training on older patients with major depression. Arch Intern Med. 1999;159:2349–56.

55. Carek PJ, Laibstain SE, Carek SM. Exercise for the treatment of depression and anxiety. J Psychiatr Med. 2011;44:15–26.

56. Lammers F, van Oppen P, Comjs HC, Smit JH, Spinhoven P, van Balkom AJ, Nolen WA, Zitman FG, Beekman AT, Penninx BW. Comorbidity patterns of anxiety and depressive disorders in a large cohort study: the Netherlands study of depression and anxiety (NEDAS). J Clin Psychiatry. 2011;72(3):348–51.

57. Verduijn J, Verhoeven J, Milanesech V, Schoevers RA, van Hentem AM, Beekman ATF, Penninx BWJH. Reconsidering the diagnosis of major depressive disorder across diagnostic boundaries: full recovery is the exception rather than the rule. BMC Med. 2017;15(1):215.

58. Scholten WD, Batelaan NM, Penninx BW, van Balkom AJ, Smit JH, Schoevers RA, van Oppen P. Diagnostic instability of recurrence and the impact on recurrence rates in depressive and anxiety disorders. J Affect Disord. 2016;195:185–90.

59. Srawn JR, Weilge JA, Wehry AM, Keeshin BR, Rynn MA. Efficacy and tolerability of antidepressants in pediatric anxiety disorders: a systematic review and meta-analysis. Depress Anxiety. 2015;32(3):149–57.

60. Lambert ME, Wood J. Incorporating patient preferences into randomized trials. J Clin Epidemiol. 2005;58(2):163–6.

61. Wittchen HU. Reliability and validity studies of the WHO—composite international diagnostic interview (CIDI): a critical review. J Psychiatr Res. 1994;28:857–84.

62. Lyketsos CG, Nestadt G, Cow JI, Heitkoff K, Eaton WW. The life-chart method for measuring illness course and duration. JAMA. 1996;276:477–86.

63. Beck AT, Epstein N, Brown G, Steer RA. An inventory for measuring clinical anxiety: psychometric properties. J Consult Clin Psychol. 1988;56:893–7.
Author/s:  
Lever-van Milligen, BA; Verhoeven, JE; Schmaal, L; van Velzen, LS; Revesz, D; Black, CN; Han, LKM; Horsfall, M; Batelaan, NM; van Balkom, AJLM; van Schaik, DJF; van Oppen, P; Penninx, BWJH

Title:  
The impact of depression and anxiety treatment on biological aging and metabolic stress: study protocol of the Mood treatment with antidepressants or running (MOTAR) study

Date:  
2019-12-30

Citation:  
Lever-van Milligen, B. A., Verhoeven, J. E., Schmaal, L., van Velzen, L. S., Revesz, D., Black, C. N., Han, L. K. M., Horsfall, M., Batelaan, N. M., van Balkom, A. J. L. M., van Schaik, D. J. F., van Oppen, P. & Penninx, B. W. J. H. (2019). The impact of depression and anxiety treatment on biological aging and metabolic stress: study protocol of the Mood treatment with antidepressants or running (MOTAR) study. BMC PSYCHIATRY, 19 (1), https://doi.org/10.1186/s12888-019-2404-0.

Persistent Link:  
http://hdl.handle.net/11343/247307

File Description:  
published version

License:  
CC BY